Focused On-demand Library for Transcription initiation factor TFIID subunit 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P49848

UPID:

TAF6_HUMAN

Alternative names:

RNA polymerase II TBP-associated factor subunit E; Transcription initiation factor TFIID 70 kDa subunit; Transcription initiation factor TFIID 80 kDa subunit

Alternative UPACC:

P49848; A4D2B2; A4D2B3; B4DT11; D6W5U2; Q6AI29

Background:

Transcription initiation factor TFIID subunit 6, also known as TAF6, plays a pivotal role in the initiation of RNA polymerase II-dependent transcription. It is a part of the TFIID basal transcription factor complex, crucial for recognizing and binding promoters, facilitating the assembly of the pre-initiation complex. TAF6's ability to form homodimers connects various modules of the TFIID complex, establishing a structural core essential for transcriptional regulation.

Therapeutic significance:

TAF6's involvement in transcriptional regulation and apoptosis, particularly through its role in up-regulating genes like GADD45A and CDKN1A/p21, highlights its potential in influencing cell fate decisions. Its association with Alazami-Yuan syndrome underscores the therapeutic significance of understanding TAF6's function. Exploring TAF6's mechanisms could unveil novel therapeutic strategies for managing diseases linked to transcriptional dysregulation.